HORIZON 21 CONSORTIUM

The Horizon 21 Consortium was born from a collaboration between clinicians from various European centers dedicated to adults and seniors with Down syndrome (DS)..

Their collaboration started in 2014 when they participated in the i-TAD project: Investigating common mechanisms in Trisomy 21 and Alzheimer’s disease (Horizon 2020 call for proposals). The group then took the name of Horizon 21.

The Horizon 21 programme currently brings together 9 teams from different European research sites, led by clinical researchers.
The programme develops collaborations with other clinicians, in Europe and in the rest of the world.

  • Antonia Coppus, Dichterbij, Center for Intellectual Disabilities, Gennep.
  • Frode Larsen, Ageing and Health Norvegian, National Advisory Unit, Oslo
  • Marie McCarron, Trinity Research, Trinity College, Dublin
  • Shahid Zaman, Cambridge Intellectual & Developmental Disabilities Research Group Department of Psychiatry, University of Cambridge.
  • Andre Strydom, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology & Neuroscience – Kings College London.
  • Anne-Sophie Rebillat, Institut Jérôme Lejeune, Centre de consultation et de recherche pour la Trisomie 21, Paris
  • Juan FORTEA, Alzheimer Down Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Fundació Catalana Síndrome de Down, Universitat Autònoma de Barcelona
  • Henrik ZETTERBERG, Institute of Neuroscience and Physiology, Götenborg

ONGOING PROJECTS

Genetic markers : large-scale genotyping of DS persons in order to identify risk or protective factors of Alzheimer disease.

 

Harmonisation of neuropsychologic evaluation tools and news tools planification

 

Biological markers : for example, neurofilaments plasmatic levels analysis.

 

Sleep scoring : the impact of Alzheimer desease on DS adults sleep.

CONTACT

 

Andre STRYDOM : andre.strydom@kcl.ac.uk

Juan FORTEA ORMAECHEA : jfortea@santpau.cat

Anne-SophieREBILLAT : annesophie.rebillat@institutlejeune.org

Mary MC CARRON : mccarrm@tcd.ie

Antonia COPPUS : antonie.Coppus@radboudumc.nl

Johannes LEVIN : johannes.Levin@med.uni-muenchen.de

Shahid ZAMAN : shz10@medschl.cam.ac.uk

Frode LARSEN : frode.larsen@aldringoghelse.no

HenrikZETTERBERG : henrik.zetterberg@clinchem.gu.se

HORIZON 21

The Horizon 21 Consortium was born from a collaboration between clinicians from various European centres offering a consultation dedicated to Down Syndrom adults and seniors.

 

This program aims at identifying the factors that have influence on Alzheimer disease development for DS persons, and developing medical testing in order to prevent and/or decrease the disease outbreak for this type of persons.

ALZHEIMER DISEASE AND DOWN SYNDROM

 

DS patients present a higher risk to develop Alzheimer disease precociously. That is, their chromosome 21 carries the APP gene, wich is the forerunner of the beta-amyloïd protein which is stacked in the brain of Alzheimer disease patients. This gene being overexpressed, patients produce excessive beta-amyloïd protein.

This type of persons often show Alzheimer disease around age 55. After age 65, the rate of DS persons who suffer from Alzheimer disease is up to 80% – compared to less than 4% for general population.

HORIZON 21 RESEARCH CENTRES ALL OVER THE WORLD

Horizon 21 research centres all over Europe



Click on the map for more information

The Horizon 21 consortium gathers 9 European countries.

Mary MC CARRON

Trinity Research, Ageing & Intellectual Disabilities
Trinity College

Dublin – Ireland

Agneta NORDBERG

Division of Alzheimer Neurobiology, and Department of Geriatric Medicine,
Karolinska Institute Hospital Huddinge

Stockholm – Sweden

Andre STRYDOM

Department of Forensic and Neuro-developmental Sciences
Institute of Psychiatry Psychology and Neuroscience
Kings College

London – England

Anne-Sophie REBILLAT
Geriatric outpatient clinic, Institut Jérôme Lejeune

Paris – France

Ellen Melbye LANGBALLE

Ageing and Health Norwegian National Advisory Unit
Vestfold Hospital Trust

Tønsberg – Norway
Oslo University Hospital – Oslo, Norway

Henrik ZETTERBERG
Institute of Neuroscience and Physiology
Department of Psychiatry and Neurochemistry
University of Gothenburg

Mölndal – Sweden

Johannes LEVIN

Department of Neurology,
Ludwig-Maximilians-Universität München

Munich – Deutschland

Juan FORTEA

Alzheimer Down Unit, Department of Neurology,
Hospital de la Santa Creu i Sant Pau
Fundacio Catalana Sindrome de Down

Barcelona – Spain

Shahid ZAMAN

Disabilities Research Group Department of Psychiatry,
University of Cambridge

Cambridge – England

Tonnie COPPUS

Dichterbij, Center for Intellectual Disabilities

Gennep – The Netherlands